Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.

Why Abbott Laboratories Will Keep Running in 2014

While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a closer look at particularly stock-shaking upgrades and downgrades -- just in case their reasoning behind the call makes sense.

What: Shares of Abbott Laboratories (NYSE: ABT  ) opened up slightly this morning after Morgan Stanley upgraded the health care giant from equal weight to overweight.

So what: Along with the upgrade, analyst David Lewis planted a price target of $45 on the stock, representing about 14% worth of upside to yesterday's close. While value investors might be turned off by the stock's surge since October, Lewis believes there's more room to run given Abbott's seemingly underappreciated growth prospects.

Now what: Morgan Stanley sees headwinds ahead for Abbott in the near term, but thinks that its long-term risk/reward trade-off is attractive at this point. "ABT's 40% emerging market revenue mix is largely unhedged, implying '13 FX moves could pressure 1H margins, in line with [Covidien (NYSE: COV  ) ] and [Johnson & Johnson (NYSE: JNJ  ) ] commentary," noted Lewis. "We are comfortable with the consensus '14 outlook for revenue growth >5% and EPS at $2.21/up 10%." With stock up about 10% over the past month alone, and trading at a forward P/E near 20, however, Fools might want to wait for a wider margin of safety before betting on it.

More compelling income opportunities

One of the dirty secrets that few finance professionals will openly admit is the fact that dividend stocks as a group handily outperform their non-dividend paying brethren. The reasons for this are too numerous to list here, but you can rest assured that it's true. However, knowing this is only half the battle. The other half is identifying which dividend stocks in particular are the best. With this in mind, our top analysts put together a free list of nine high-yielding stocks that should be in every income investor's portfolio. To learn the identity of these stocks instantly and for free, all you have to do is click here now.

Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2799615, ~/Articles/ArticleHandler.aspx, 3/31/2015 3:08:55 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!